Activation of FXR is an effective treatment of hyperlipidemia [81,82].The FXR agonist 6-ethyl-CDCA, known as obeticholic acid (OCA), additionally activates the GPBAR1/TGR5 [83] and is responsible for unwanted effects of synthetic FXR ligands such as itching. The gene discussed is NR1H4; the disease is hyperlipidemia.